Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 218 matching drugs for HSPD1 — including drugs targeting any of its 54 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
disulfiram, copper, alkylating agents HSPD1 Direct 1
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
sunitinib KDR SSL via KDR yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab ABL1 SSL via ABL1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KDR SSL via KDR 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) ABL1 SSL via ABL1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KDR SSL via KDR 4
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine KDR SSL via KDR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ABL1 SSL via ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FYN SSL via FYN 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KDR SSL via KDR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAPK14 SSL via MAPK14 3
pembrolizumab, belzutifan, lenvatinib KDR SSL via KDR 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ABL1 SSL via ABL1 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan KDR SSL via KDR 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 KDR SSL via KDR 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment ABL1 SSL via ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FYN SSL via FYN 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment MAPK14 SSL via MAPK14 2
bryostatin 1, paclitaxel CASP8 SSL via CASP8 2
cabozantinib KDR SSL via KDR yes 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib KDR SSL via KDR 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib KDR SSL via KDR 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib TNK2 SSL via TNK2 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a KDR SSL via KDR 2
lenvatinib, pembrolizumab KDR SSL via KDR 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate KDR SSL via KDR 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a KDR SSL via KDR 2
nintedanib KDR SSL via KDR yes 2
nintedanib, pembrolizumab KDR SSL via KDR 2
pazopanib KDR SSL via KDR yes 2
pembrolizumab, lenvatinib KDR SSL via KDR 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu KDR SSL via KDR 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin KDR SSL via KDR 2
ramucirumab KDR SSL via KDR yes 2
ramucirumab, paclitaxel KDR SSL via KDR 2
regorafenib ABL1 SSL via ABL1 yes 2
regorafenib KDR SSL via KDR yes 2
regorafenib, laboratory biomarker analysis ABL1 SSL via ABL1 2
regorafenib, laboratory biomarker analysis KDR SSL via KDR 2
sorafenib, administered orally, ct/mri KDR SSL via KDR 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy KDR SSL via KDR 2
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) KDR SSL via KDR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ABL1 SSL via ABL1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib FYN SSL via FYN 1
afatinib, dasatinib, palbociclib, everolimus, olaparib MAPK14 SSL via MAPK14 1
agent-797, botensilimab, balstilimab, ramucirumab, paclitaxel KDR SSL via KDR 1
atezolizumab, cabozantinib KDR SSL via KDR 1
atezolizumab, tivozanib KDR SSL via KDR 1
axitinib KDR SSL via KDR yes 1
axitinib, avelumab KDR SSL via KDR 1
axitinib, axitinib plus lomustine KDR SSL via KDR 1
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil KDR SSL via KDR 1
bevacizumab, cediranib, cediranib maleate, olaparib KDR SSL via KDR 1
bevacizumab, dasatinib, placebo ABL1 SSL via ABL1 1
bevacizumab, dasatinib, placebo FYN SSL via FYN 1
bevacizumab, dasatinib, placebo MAPK14 SSL via MAPK14 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib KDR SSL via KDR 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging KDR SSL via KDR 1
biospecimen collection, computed tomography, magnetic resonance imaging, nivolumab, paclitaxel, questionnaire administration, ramucirumab KDR SSL via KDR 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography KDR SSL via KDR 1
bosutinib ABL1 SSL via ABL1 yes 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab KDR SSL via KDR 1
cabozantinib, durvalumab, tremelimumab KDR SSL via KDR 1
cabozantinib, nivolumab KDR SSL via KDR 1
cabozantinib, pembrolizumab KDR SSL via KDR 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab KDR SSL via KDR 1
cediranib, cediranib, lomustine chemotherapy, placebo cediranib KDR SSL via KDR 1
cediranib, lomustine KDR SSL via KDR 1
cisplatin, pemetrexed disodium, sorafenib KDR SSL via KDR 1
crenolanib, ramucirumab, paclitaxel KDR SSL via KDR 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride ABL1 SSL via ABL1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride FYN SSL via FYN 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride MAPK14 SSL via MAPK14 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method ABL1 SSL via ABL1 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method FYN SSL via FYN 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method MAPK14 SSL via MAPK14 1
dasatinib, laboratory biomarker analysis, physiologic testing ABL1 SSL via ABL1 1
dasatinib, laboratory biomarker analysis, physiologic testing FYN SSL via FYN 1
dasatinib, laboratory biomarker analysis, physiologic testing MAPK14 SSL via MAPK14 1
dasatinib, mfolfox6 ABL1 SSL via ABL1 1
dasatinib, mfolfox6 FYN SSL via FYN 1
dasatinib, mfolfox6 MAPK14 SSL via MAPK14 1
dasatinib, pharmacological study ABL1 SSL via ABL1 1
dasatinib, pharmacological study FYN SSL via FYN 1
dasatinib, pharmacological study MAPK14 SSL via MAPK14 1
dasatinib, temozolomide, placebo, radiation therapy ABL1 SSL via ABL1 1
dasatinib, temozolomide, placebo, radiation therapy FYN SSL via FYN 1
dasatinib, temozolomide, placebo, radiation therapy MAPK14 SSL via MAPK14 1
disulfiram, copper, alkylating agents APP SSL via APP 1
durvalumab, olaparib, cediranib KDR SSL via KDR 1
entrectinib TNK2 SSL via TNK2 yes 1
erdafitinib KDR SSL via KDR 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.